Group ID|Group Name|Treatment Sequence|Treatment Age|Treatment Type|Treatment Quantity|Treatment Unit|Treatment Application|Treatment Remarks|No of individuals in study|Species|Strain|Sex|Age|Group Endpoints|Individual ID|Group ID|Age at death|Pathology type |Pathology location|Pathology Description|
17-4-1|n/a,n/a|Sequence:1, Age:500,Type:X-rays whole body,Quantity:1.8,Unit:grays,Application:External exposure local, Remarks:mean dose BM from unilateral, dogs age 12-20 months|6 (0 in ERA)|Dog|Dog, Beagle|Both|Young Adult|haematological parameters, bone marrow GM-CFC, CFU-F serum CSA sequential studies over one year|No information on individuals available for this study
17-4-2|n/a,n/a|Sequence:1, Age:500,Type:X-rays whole body,Quantity:1.7,Unit:grays,Application:External exposure, Remarks:mean dose BM from bilateral, dogs age 12 -20 months|3 (0 in ERA)|Dog|Dog, Beagle|Both|Young Adult|haematological parameters, bone marrow GM-CFC, CFU-F serum CSA sequential studies over one year|No information on individuals available for this study
		
